Sangamo Therapeutics, Inc. (SGMO.US) — Analysis $SGMO
Analyst Opinions (Latest Updates – April 2026)
Average Price Target: $3.75 – $5.50 (some estimates go up to $6)
Highest Target: $10 (HC Wainwright & Co., February 2026)
Lowest Target: $1
Number of Analysts: 4–11 (varies by source)
Consensus Rating: Generally Overweight / Moderate Buy or Outperform
Recent Notable Ratings:
HC Wainwright reiterates Buy with a $10 target (Feb 2026)
Barclays downgraded to Equal-Weight (Nov 2025)
Zacks downgraded to Strong Sell (Apr 2026)
Potential Upside:
Massive upside potential (1300%–2000% based on target prices) due to the extremely low share price. However, opinions are mixed, analyst coverage is relatively limited, and the company is small with high risk.
⸻
Chart Pattern & Technical Analysis
Overall Trend: Strong downtrend (falling channel) in the medium and long term. The stock is trading below all key moving averages (50-day, 200-day), with no clear strong support.
Technical Indicators: Mostly signaling Strong Sell (Moving Averages, RSI, MACD).
Chart Pattern: No clear bullish pattern (such as cup & handle or breakout). The chart shows continuous decline with high volatility — typical of biotech penny stocks.
Key Levels:
Resistance: $0.33 – $0.43
Support: $0.21 – $0.25
#Stocks #StockMarket #Trading #Investing #PennyStocks #BiotechStocks #StockGroups
English
